Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-näive subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents

Diabetes Care

Volumn 38, Issue 12, 2015, Pages 2274-2281

  Rosenstock, Julio ^a   Franco, Denise ^b   Korpachev, Vadym ^c   Shumel, Brad ^d   Ma, Yuhui ^e   Baughman, Robert ^e   Amin, Nikhil ^e   McGill, Janet B ^f  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b CPCLIN Clinical Research Center   (Brazil)

^c V P Komisarenko Institute of Endocrinology and Metabolism of the Ukraine Academy of Medical Sciences   (Ukraine)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e MannKind Corporation   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MICROSPHERE; PLACEBO; SULFONYLUREA; TECHNOSPHERE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; POWDER;

ADULT; ARTICLE; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; AGED; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POWDER;

ADMINISTRATION, INHALATION; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, REGULAR, HUMAN; MALE; METFORMIN; MICROSPHERES; MIDDLE AGED; PLACEBOS; POWDERS; TREATMENT OUTCOME;

EID: 84955681531     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0629     Document Type: Article

References (35)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149.
2. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012.
3. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80, 000 people. Diabetes Care 2013;36: 3411-3417.
4. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540.
5. Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract 2011; 94:352-363.
6. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-948.
7. Cefalu WT. Evaluation of alternative strategies for optimizing glycemia: Progress to date. Am J Med 2002;113(Suppl. 6A):23S-35S.
8. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care 2005;28: 2543-2545.
9. Peyrot M, Rubin RR, Lauritzen T, et al.; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679.
10. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treatto-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
11. Bretzel RG, Nuber U, LandgrafW, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008;371:1073-1084.
12. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-183.
13. Kipnis DM. Insulin secretion in diabetes mellitus. Ann Intern Med 1968;69:891-901.
14. Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med 2008; 121(Suppl.):S9-S19.
15. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 1993;10:535-539.
16. Pfützner A, Mann AE, Steiner SS. Technosphere/Insulin-a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002;4:589-594.
17. Kaur N, Zhou B, Breitbeil F, et al. A delineation of diketopiperazine self-assembly processes: understanding the molecular events involved in Nepsilon-(fumaroyl)diketopiperazine of L-Lys (FDKP) interactions. Mol Pharm 2008;5:294-315.
18. Boss AH, Rave K, Cheatham WW, Heise T. Inhaled Technosphere insulin: glucose elimination at the right time? (Abstract). Diabetes 2005; 54(Suppl. 1):A109.
19. Rave K, Heise T, Pfützner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 2007;30:2307-2308.
20. Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere/Insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110:17-21.
21. Potocka E, Hovorka R, Baughman RA, et al. Technosphere insulin suppresses endogenous glucose production earlier than a rapid-acting analog (lispro) and an inhaled insulin (Exubera). Diabetologia 2009;52(Suppl. 1):S374.
22. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
23. Miller MR, Hankinson J, Brusasco V, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
24. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
25. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011; 34:2508-2514.
26. Bastyr EJ 3rd, Stuart CA, Brodows RG, et al.; IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23:1236-1241.
27. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-2029.
28. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26:881-885.
29. Allemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: A systematic review and meta-analysis. Curr Med Res Opin 2009;25:2903-2913.
30. Bosi E, Scavini M, Ceriello A, et al.; PRISMA Study Group. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: The PRISMA randomized trial. Diabetes Care 2013;36:2887-2894.
31. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: Results from the Structured Testing Program study. Diabetes Care 2011;34:262-267.
32. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: A multicentre randomised trial. Lancet 2010;375:2244-2253.
33. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-2362.
34. Gross JL, Nakano M, Colon-Vega G, et al. Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial. Diabetes Technol Ther 2009;11(Suppl 2): S27-S34.
35. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial. Diabetes Obes Metab 2012;14: 163-173.